RxDoctor Payments Data

Anil George, MD

Cardiovascular Disease · Greenville, NCNPI 1154307684

Payments from drug & device makers

$9,367in general payments, 2019–2025

Across 155 payments — averaging $60.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
  • Merck$423
  • Novartis$384
  • Medtronic$309
  • Johnson & Johnson$228
  • E.r. Squibb & Sons, L.L.C.$220
  • plus $766 from 18 others

What the payments were for

  • Speaking & faculty fees$6,75072%
  • Food & beverage$2,61728%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,367 in reported general payments places this provider in the 70th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$262,903
Medicare patients
2,377
Services billed
5,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban318$296,293
EntrestoSacubitril/Valsartan185$191,806
XareltoRivaroxaban90$75,120
VerquvoVericiguat62$47,427
FarxigaDapagliflozin Propanediol23$31,447
JardianceEmpagliflozin43$27,527
BrilintaTicagrelor20$16,864
MultaqDronedarone Hcl14$15,531
Metoprolol Succinate459$3,899
Ranolazine ErRanolazine48$3,595
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine15$2,103
Atorvastatin Calcium188$1,822
Isosorbide Mononitrate ErIsosorbide Mononitrate153$1,722
Nebivolol Hcl36$1,418
Losartan Potassium200$1,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$69$296,293318 claims
NovartisEntresto$384$191,806185 claims
Johnson & JohnsonXarelto$228$75,12090 claims
AstraZenecaFarxiga, Brilinta$32$48,31143 claims
MerckVerquvo$423$47,42762 claims
Sanofi-aventis U.S. LLCMultaq$34$15,53114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →